FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa - Poll - MDSpire

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 2 min

Share

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Toward Participatory Precision Health With Co-Designed Recommendations: Systematic Review of Just-in-Time Adaptive Interventions in Adolescents and Young Adults

The optimal exercise for improving inhibitory control in children and adolescents with NDDs: a systematic review and network meta-analysis